LGVN FY 2022 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-6.4% YoY

Gross Profit

$497,00040.7% margin

Operating Income

-$18M-1476.5% margin

Net Income

-$19M-1541.3% margin

EPS (Diluted)

$-9.00

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$27M

Total Liabilities

$7M

Stockholders' Equity

$21M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	-6.4%
Gross Profit	$497,000	$590,000	-15.8%
Operating Income	-$18M	-$17M	-3.4%
Net Income	-$19M	-$17M	-10.5%